日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Generation and preclinical characterization of a novel bispecific CD19-TCRgammadelta antibody for the treatment of B cell acute lymphoblastic leukemia

用于治疗B细胞急性淋巴细胞白血病的新型双特异性CD19-TCRγδ抗体的制备和临床前表征

Kauer, Joseph; Vogt, Fabian; Hörner, Sebastian; Schmidt, Valentin; Müller-Tidow, Carsten; Raffel, Simon; Salih, Helmut R; Jung, Gundram; Pflügler, Martin

Characterization of TROP-2 bispecific T cell engagers for immunotherapy of triple negative breast and bladder cancer

TROP-2双特异性T细胞衔接器在三阴性乳腺癌和膀胱癌免疫治疗中的应用特性分析

Ávila-Nieto, Carlos; Jung, Gundram; Salih, Helmut R; Hagelstein, Ilona

CLEC12A-directed immunocytokine with target cell-restricted IL-15 activity for treatment of acute myeloid leukemia

靶向CLEC12A的免疫细胞因子,具有靶细胞限制性IL-15活性,用于治疗急性髓系白血病

Klimovich, Boris; Anton, Leonard; Jung, Jinwon; Lim, Yangmi; Lee, Bora; Won, Jonghwa; Zekri, Latifa; Chashchina, Anna; Pflügler, Martin; Heitmann, Jonas S; Jung, Gundram; Salih, Helmut R

Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine

TP53突变状态对老年AML患者在接受地西他滨治疗时加用全反式维甲酸或丙戊酸的影响

Bresser, Helena; Schmoor, Claudia; Grishina, Olga; Pfeifer, Dietmar; Thomas, Johanna; Rehman, Usama-Ur; Crysandt, Martina; Jost, Edgar; Thol, Felicitas; Heuser, Michael; Götze, Katharina S; Schlenk, Richard F; Salih, Helmut R; Schittenhelm, Marcus M; Heil, Gerhard; Schwaenen, Carsten; Müller-Tidow, Carsten; Brugger, Wolfram; Kündgen, Andrea; de Wit, Maike; Giagounidis, Aristoteles; Scholl, Sebastian; Neubauer, Andreas; Krauter, Jürgen; Bug, Gesine; May, Annette M; Wäsch, Ralph; Duyster, Justus; Döhner, Konstanze; Ganser, Arnold; Döhner, Hartmut; Hackanson, Björn; Becker, Heiko; Lübbert, Michael

Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody

利用Fc优化CD276(B7-H3)抗体诱导NK细胞对急性髓系白血病的反应性

Stefańczyk, Sylwia A; Hagelstein, Ilona; Lutz, Martina S; Müller, Stefanie; Holzmayer, Samuel J; Jarjour, Grace; Zekri, Latifa; Heitmann, Jonas S; Salih, Helmut R; Märklin, Melanie

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin

对接受强化化疗联合米哚妥林治疗的FLT3-ITD突变型急性髓系白血病(AML)患者进行可测量的残留病灶监测

Rücker, Frank G; Bullinger, Lars; Cocciardi, Sibylle; Skambraks, Sabrina; Luck, Tamara J; Weber, Daniela; Krzykalla, Julia; Pozek, Ema; Schneider, Isabelle; Corbacioglu, Andrea; Gaidzik, Verena I; Meid, Annika; Aicher, Sophia; Stegelmann, Frank; Schrade, Anika; Theis, Frauke; Fiedler, Walter; Salih, Helmut R; Wulf, Gerald; Salwender, Hans; Schroeder, Thomas; Götze, Katharina S; Kühn, Michael W M; Lübbert, Michael; Schlenk, Richard F; Benner, Axel; Thol, Felicitas; Heuser, Michael; Ganser, Arnold; Döhner, Hartmut; Döhner, Konstanze

An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer

一种Fc修饰的单克隆抗体作为胰腺癌的新型治疗选择

Lutz, Martina S; Wang, Kevin; Jung, Gundram; Salih, Helmut R; Hagelstein, Ilona

Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients

基于仓库的、免疫肽组指导的个性化肽疫苗设计在慢性淋巴细胞白血病患者的临床试验评估中显示出可行性。

Heitmann, Jonas S; Jung, Susanne; Wacker, Marcel; Maringer, Yacine; Nelde, Annika; Bauer, Jens; Denk, Monika; Hoenisch-Gravel, Naomi; Richter, Marion; Oezbek, Melek T; Dubbelaar, Marissa L; Bilich, Tatjana; Pumptow, Marina; Martus, Peter; Illerhaus, Gerald; Denzlinger, Claudio; Steinbach, Francesca; Aulitzky, Walter-Erich; Müller, Martin R; Dörfel, Daniela; Rammensee, Hans-Georg; Salih, Helmut R; Walz, Juliane S

Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3)

首次人体临床试验方案,旨在评估双特异性 CD276xCD3 抗体 CC-3 在结直肠癌患者中的安全性、耐受性和初步疗效 (CoRe_CC-3)

Jung, Susanne; Schlenk, Richard F; Hackenbruch, Christopher; Roldan Pinzon, Sandra S L; Bitzer, Michael; Pflügler, Martin; Walz, Juliane S; Jung, Gundram; Heitmann, Jonas S; Salih, Helmut R

FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion

FusionVAC22_01:一项 I 期临床试验,评估基于 DNAJB1-PRKACA 融合转录本的肽疫苗联合免疫检查点抑制剂治疗纤维板层型肝细胞癌和其他携带致癌驱动融合基因的肿瘤的疗效。

Hackenbruch, Christopher; Bauer, Jens; Heitmann, Jonas S; Maringer, Yacine; Nelde, Annika; Denk, Monika; Zieschang, Lisa; Kammer, Christine; Federmann, Birgit; Jung, Susanne; Martus, Peter; Malek, Nisar P; Nikolaou, Konstantin; Salih, Helmut R; Bitzer, Michael; Walz, Juliane S